Mycoplasmas are a specific and unique species of bacteria - the smallest free-living organism known on the planet. The primary differences between mycoplasmas and other bacteria is that bacteria have a solid cell-wall structure and they can grow in the simplest culture media. Mycoplasmas however, do not have a cell wall, and like a tiny jellyfish with a pliable membrane, can take on many different shapes which make them difficult to identify, even under a high powered electron microscope. Mycoplasmas can also be very hard to culture in the laboratory and are often missed as pathogenic causes of diseases for this reason.
The accepted name was chosen because Mycoplasmas were observed to have a fungi-like structure (Mycology is the study of fungi - hence "Myco") and it also had a flowing plasma-like structure without a cell wall - hence "plasma". The first strains were isolated from cattle with Arthritis and pleuro-pneumonia in 1898 at the Pasteur Institute. The first human strain was isolated in 1932 from an abscessed wound. The first connection between mycoplasmas and rheumatoid diseases was made in 1939 by Drs. Swift and Brown. Unfortunately, mycoplasmas didn't become part of the medical school curriculum until the late 1950's when one specific strain was identified and proven to be the cause of atypical pneumonia, and named Mycoplasma pneumonia. The association between immunodeficiency and autoimmune disorders with mycoplasmas was first reported in the mid 1970s in patients with primary hypogammaglobulinemia (an autoimmune disease) and infection with four species of mycoplasma that had localized in joint tissue. Since that time, scientific testing methodologies have made critical technological progress and along with it, more mycoplasma species have been identified and recorded in animals, humans and even plants.
While Mycoplasma pneumonia is certainly not the only species causing disease in humans, it makes for a good example of how this stealth pathogen can move out of it's typical environment and into other parts of the body and begin causing other diseases. While residing in the respiratory tract and lungs, Mycoplasma pneumonia remains an important cause of pneumonia and other airway disorders, such as tracheobronchitis, pharyngitis and asthma. When this stealth pathogen hitches a ride to other parts of the body, it is associated with non-pulmonary manifestations, such as blood, skin, joint, central nervous system, liver, pancreas, and cardiovascular syndromes and disorders. Even as far back as 1983, doctors at Yale noted:
"Over the past 20 years the annual number of reports on extrapulmonary symptoms during Mycoplasma (M.) pneumoniae disease has increased. Clinical and epidemiological data indicate that symptoms from the skin and mucous membranes, from the central nervous system, from the heart, and perhaps from other organs as well are not quite uncommon manifestations of M. pneumoniae disease." (15)
This single stealth pathogen has been discovered in the urogenital tract of patients suffering from inflammatory pelvic disease, urethritis, and other urinary tract diseases (8) It has been discovered in the heart tissues and fluid of patients suffering from cardititis, pericarditis, tachycardia, hemolytic anemia, and other coronary heart diseases.(9, 10, 14) It has been found in the cerebrospinal fluid of patients with meningitis and encephalitis, seizures, ALS, Alzheimer's and other central nervous system infections, diseases and disorders.(11-13) It has even been found regularly in the bone marrow of children with leukemia.(16- 18) It is amazing that one single tiny bacteria can be the cause of so many seemingly unrelated diseases in humans. But as with all mycoplasma species, the disease is directly related to where the mycoplasma resides in the body and which cells in the body it attaches to or invades.
Today, over 100 documented species of mycoplasmas have been recorded to cause various diseases in humans, animals, and plants. Mycoplasma pneumonia as well as at least 7 other mycoplasma species have now been linked as a direct cause or significant co-factor to many chronic diseases including, Rheumatoid Arthritis , Alzheimer's, multiple sclerosis, fibromyalgia, chronic fatigue, diabetes, Crohn's Disease, ALS, nongonoccal urethritis, asthma, lupus, infertility, AIDS and certain cancers and leukemia, just to name a few.(1-6)
In 1997, the National Center for Infectious Diseases, Centers for Disease Control and Prevention's journal, Emerging Infectious Diseases, published the article, Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety, by Drs. Baseman and Tully who stated:
"Nonetheless, mycoplasmas by themselves can cause acute and chronic diseases at multiple sites with wide-ranging complications and have been implicated as cofactors in disease. Recently, mycoplasmas have been linked as a cofactor to AIDS pathogenesis and to malignant transformation, chromosomal aberrations, the Gulf War Syndrome, and other unexplained and complex illnesses, including chronic fatigue syndrome, Crohn's disease, and various arthritides."
Mycoplasmas, unlike viruses, can grow in tissue fluids (blood, joint, heart, chest and spinal fluids) and can grow inside any living tissue cell without killing the cells, as most normal bacteria and viruses will do. Mycoplasmas are frequently found in the oral and genito-urinary tracts of normal healthy people and are found to infect females four times more often than males, which just happens to be the same incidence rate in Rheumatoid Arthritis , fibromyalgia, Chronic Fatigue and other related disorders.(7)
Mycoplasmas are parasitic in nature and can attach to specific cells without killing the cells and thus their infection process and progress can go undetected. In some people the attachment of mycoplasmas to the host cell acts like a living thorn; a persistent foreign substance, causing the host's immune defense mechanism to wage war. This allergic type of inflammation often results in heated, swollen, and painful inflamed tissues, like those found in rheumatoid diseases, fibromyalgia and many other autoimmune disorders like lupus and MS, Crohn's and others. In such cases the immune system begins attacking itself and/or seemingly healthy cells. Some species of mycoplasmas also have the unique ability to completely evade the immune system. Once they attach to a host cell in the body, their unique plasma and protein coating can then mimic the cell wall of the host cell and the immune system cannot differentiate the mycoplasma from the body's own host cell.
Mycoplasmas are parasitic in nature because they rely on the nutrients found in host cells including cholesterol, amino acids, fatty acids and even DNA. They especially thrive in cholesterol rich and arginine-rich environments. Mycoplasmas can generally be found in the mucous membrane in the respiratory tract. They need cholesterol for membrane function and growth, and there is an abundance of cholesterol in the bronchial tubes of the respiratory tract. Once attached to a host cell, they then begin competing for nutrients inside the host cells. As nutrients are depleted, then these host cells can begin to malfunction, or even change normal functioning of the cell, causing a chain reaction with other cells (especially within the immune and endocrine systems). Mycoplasmas can even cause RNA and DNA mutation of the host cells and have been linked to certain cancers for this reason. Mycoplasmas can also invade and live inside host cells which evade the immune system, especially white blood cells. Once inside a white blood cell, mycoplasmas can travel throughout the body and even cross the blood/brain barrier, and into the central nervous system and spinal fluid.
Baseman, Joel, et.al., Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety, CDC, Journal of Infectious Diseases, Vol 3, No.1, Feb 1997
S-C. Mycoplasmas and AIDS. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:525-45.
Nicolson G, Nicolson NL. Diagnosis and treatment of mycoplasmal infections in Gulf War illness-CFIDS patients. Intl J Occup Med Immunol Toxicol 1996;5:69-78.
Wear DJ, et.al. Mycoplasmas and oncogenesis:persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 1995;92:10197-201.
Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in-utero measles virus exposure. Lancet 1996;348:516-7.
Taylor-Robinson D. Mycoplasmas in Rheumatoid Arthritis and other human arthritides. J Clin Pathol 1996;49:781-2.
Dr.Harold Clark, The Intercessor, June 1993, The Road Back Foundation, Delaware OH.
Goulet M, et.al., Isolation of Mycoplasma pneumoniae from the human urogenital tract. J Clin Microbiol 1995;33:2823-5
Daxbock F, et.al., Severe hemolytic anemia and excessive leukocytosis masking mycoplasma pneumonia. Ann Hematol. 2001 Mar;80(3):180-2.
Higuchi ML, et.al., Detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured atherosclerotic plaques. Braz J Med Biol Res. 2000 Sep;33(9):1023-6.
Socan M, Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis. 2001 Jan 15;32(2):E31-5.
Bencina D, et.al., Intrathecal synthesis of specific antibodies in patients with invasion of the central nervous system by Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis. 2000 Jul;19(7):521-30
Smith R, et.al., Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila). 2000 Apr;39(4):195-201.
Umemoto M, Advanced atrioventricular block associated with atrial tachycardia caused by Mycoplasma pneumoniae infection. Acta Paediatr Jpn. 1995 Aug;37(4):518-20.
Lind K. Manifestations and complications of Mycoplasma pneumoniae disease: a review.Yale J Biol Med. 1983 Sep-Dec;56(5-6):461-8.
Alexander FE. Is Mycoplasma Pneumonia associated with childhood acute lymphoblastic leukemia? Cancer Causes Control. 1997 Sep;8(5):803-11.
Hall JE, Mycoplasma pneumonia in acute childhood leukemia. Pediatr Pulmonol. 1985 Nov-Dec;1(6):333-6.
Murphy WH, Gullis C, Dabich L, Heyn R, Zarafonetis CJD. Isolation of Mycoplasma from leukemic and nonleukemia patients. J Nat Cancer Inst 1970;45:243-51.
How Mycoplasmas Interact in the Body
To understand how mycoplasmas can cause widespread disease, we must first look at the species' unique properties and interactions with host cells. Unlike viruses and bacteria, mycoplasmas are the smallest free-living and self-duplicating microorganisms, as they don't require living cells to replicate their DNA and growth.
Mycoplasmas are able to hide inside the cells of the host (patient) or to attach to the outside of host cells. Whether they live inside or outside the host cell, they depend on host cells for nutrients such as cholesterol, amino acids, etc. They compete with the host cells for these nutrients which can interfere with host cell function without killing the host cell.
A mycoplasma has very little DNA of its own, but is capable of using DNA from a host cell. When a mycoplasma takes over the DNA of the host cell, anything can happen - including causing that cell to malfunction in many different ways and/or die, or can cause DNA mutation of the host cell. Mycoplasmas attach to host cells with a tiny arm coated in protein which attaches to the protein coating of host cells. For this reason, Antibiotics like tetracycline, which are classified as "protein synthesis inhibitors" are often used against mycoplasma infections. While these Antibiotics may block this protein attachment and very slowly starve it from the nutrients it needs from host cells to thrive and replicate, it still takes a healthy immune system to actually kill the mycoplasma for good.
Mycoplasmas are highly adaptable to changing environments and can move anywhere in the body, attaching to or invading virtually any type of cell in the body. The mycoplasma adhesion proteins are very similar to human proteins. Once adhered to the host cell, the mycoplasma can completely mimic or copy the protein cell of the host cell. This can cause the immune system to begin attacking the body's own cells; an event that happens in all autoimmune diseases.
Certain Mycoplasma species can either activate or suppress host immune systems, and they may use these activities to evade host immune responses. Mycoplasmas can turn on the chain reaction called an immune system response. This includes the stimulation of pro-inflammatory cytokines (chemical messengers of the immune system) which is generally found in most autoimmune and inflammatory diseases and disorders. Mycoplasma can also attach to or invade immune system cells, like the very phagocytes (natural killer cells) that are supposed to kill them. Inside these phagocytes, they can be carried to new locations of inflammation or disease - hidden away like a spy who has infiltrated the defending army. When a mycoplasma attaches to a host cell, it generates and releases hydrogen peroxide and superoxide radicals which cause oxidative stress and damage to the surrounding tissues.
The Main Human Mycoplasma Pathogens
Pathogen / Implicated Disease (1-6)
Arthritis, chronic nongonococcal urethritis, chronic pelvic inflammatory disease, other urogenital infections and diseases, infertility, AIDS/HIV
Arthritis, Gulf War Syndrome, Fibromyalgia, Chronic Fatigue Syndrome, Lupus, AIDS/HIV, autoimmune diseases, ALS, Psoriasis and Scleroderma, Crohn's and IBS, cancer, endocrine disorders, Multiple Sclerosis, diabetes
Arthritis, TMJ disorders, Eye and ear disorders and infections, gingivitis, periodontal diseases including even cavities.
Mycoplasma hominis and Ureaplasma urealyticum
Pelvic inflammatory disease, infertility, non-gonococcal urethritis, vaginitis, cervicitis, amnionitis, pyelonephritis, post-partum septicemia, neonatal pneumonia, neonatal conjunctivitis, Reiter's syndrome, peritonitis, wound infections (C-section), low birth weight infants, and premature rupture of membranes.
Pneumonia, asthma, upper and lower respiratory diseases, heart diseases, leukemia, Steven-Johnson syndrome, polyarthritis or septic arthritis, CNS disorders and diseases, urinary tract infections, Crohn's and Irritable Bowel Syndrome, Guillain-Barr syndrome, polyradiculitis, encephalitis, and septic meningitis, autoimmune diseases.
Mycoplasma incognitus and
AIDS/HIV, urogenital infections and diseases, Autoimmune disorders and diseases
Urogenital infections and diseases, AIDS/HIV
Mycoplasma faucium, M. lipophilum and M. buccale
Diseases of the gingival crevices and respiratory tract
Krause DC, Taylor-Robinson D. Mycoplasmas which infect humans. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:417-44.
Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975;58:229-42.
Baseman, Joel, et.al., Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. CDC, Journal of Infectious Diseases, Vol 3, No.1, Feb 1997
Blanchard, A., et.al., AIDS-associated mycoplasmas. Ann.Rev.Microbiol. 1994; 48:687-712.
Hawkins, et.al., Association of mycoplasma and human immunodeficiency virus infection: detection of amplified mycoplasma fermentans DNA in blood. J.Infec.Dis. 1992: 165:581-585
Hussain AI, et.al., Mycoplasma penetrans and other mycoplasmas in urine of human immunodeficiency virus-positive children. J Clin Microbiol. 1999 May;37(5):1518-23.
(Plus other health disorders, including auto-immune disorders)
by: Scott, Donald W., M.Sc.
Donald Scott is a retired high school teacher and university professor who is currently president of the Common Cause Medical Research Foundation and adjunct professor of the Institute of Molecular Medicine. He has extensively researched neurosystemic degenerative diseases over the past five years and has authored many documents on the relationship between degenerative diseases and a pathogenic mycoplasma called Mycoplasma fermentans. His research is based upon solid government evidence. Donald Scott is a veteran of WWII and was awarded the North Atlantic Star, the Burma Star with Clasp, the 1939-1945 Volunteer Service Medal and the Victory Medal.
I - The Mycoplasma a Common Pathogenic Mycoplasma
There are 200 species of mycoplasmas. Most are innocuous and do no harm; only four or five are pathogenic. The Mycoplasma fermentans (incognitus strain) probably comes from the nucleus of the brucellosis bacteria. This disease agent is not a bacteria, and not a virus; it is a mutated form of the brucellosis bacteria, mutated with a visna virus, from which the mycoplasma, is extracted. Dr. Maurice Hilleman, chief virologist for the pharmaceutical company of Merck, Sharp and Dohme, stated that this disease agent is now carried by everybody in North America and possibly most people throughout the world. The mycoplasma used to be very innocuous. Only one person out of 500,000 would get multiple sclerosis; one out of 300,000 would develop Alzheimer's; one out of 1,000,000 would develop Creutzfeldt-Jakob disease. Before the early 1980's, nobody ever died of AIDS because it didn't exist. The mycoplasma is also the disease agent in AIDS, and I have all the documentation to prove it.
BIOWARFARE RESEARCH Between 1942 and the present time, biological warfare research has resulted in a more deadly and infectious form of the mycoplasma. They extracted this mycoplasma from the brucellosis bacteria, weaponized it and actually reduced the disease to a crystalline form. According to Dr. Shyh-Ching Lo, one of America's top, top researchers, this disease agent, the mycoplasma, causes among other things, AIDS, chronic fatigue syndrome, multiple sclerosis, Wegener's disease, Parkinson's disease, Crohn's colitis, Type I diabetes, and collagen-vascular diseases such as rheumatoid Arthritis and Alzheimer's. The mycoplasma enters into the individual cells of the body depending upon your genetic predisposition. You may develop neurological diseases if the pathogen destroys certain cells in your brain, or you may develop Crohn's colitis if the pathogen invades and destroys cells in the lower bowel. Once it gets into the cell, it can lie there doing nothing sometimes for 10, 20 or 30 years, but if a trauma occurs like an accident, or a vaccination that doesn't take, the mycoplasma can become triggered. Because it is only the DNA particle of the bacteria, it doesn't have any organelles to process its own nutrients, so it grows by uptaking preformed sterols from its host cell, literally kills the cell, and the cell ruptures and what is left gets dumped into the blood stream.
DOCUMENTED EVIDENCE My conclusions are entirely based upon official documents: 80% are United States or Canadian official government documents, and 20% are articles from peer-reviewed journals, such as the Journal of the American Medical Association, The New England Journal of Medicine, and The Canadian Medical Association Journal. The journal articles and government documents complement each other. We also have a document from Dr. Shyh-Ching Lo which names the mycoplasma as a cause of cancer. Dr. Charles Engel who is with the National Institutes of Health, Bethesda, Maryland, stated at an NIH meeting on February 7, 2000, "I am now of the view that the probable cause of Chronic Fatigue Syndrome and fibromyalgia is the mycoplasma".
II - Creation of the Mycoplasma Patent
Many doctors don't know about this mycoplasma because it was developed by the U.S. military in biological warfare experimentation, and it was not made public. This pathogenic mycoplasma disease agent was patented by the United States military by Dr. Shyh-Ching Lo, who was the top researcher for the military biological warfare research facility. I have the documented patent from the U.S. patent office. A LABORATORY-CREATED PATHOGEN BY THE U.S. MILITARY Researchers in the United States, Canada and Britain were doing biowarfare research with the brucellosis bacteria as well as with a number of other disease agents. From its inception, the biowarfare program was characterized by continuing in-depth review and participation by the most eminent scientists, medical consultants, industrial experts and government officials, and it was top secret. The U.S. Public Health Service also closely followed the progress of biological warfare research and development from the very start of the program, and the Centers for Disease Control (CDC), and the National Institutes of Health (NIH) in the United States were working with the military in weaponizing these diseases. These are diseases which have existed for thousands of years, but they have been weaponized which means they were made more contagious and more effective. And they are spreading. A program developed by the CIA and NIH to develop a deadly lethal pathogen for which humanity had no natural immunity (AIDS) was disguised as a war on cancer and was part of MKNAOMI (ref. Special Virus Cancer Program: Progress Report 8, prepared by National Cancer Institute, Viral Oncology, Etiology Area, July, 1971 and submitted to NIH Annual Report in May, 1971 and updated July, 1971).
COMMITTEE ON GOVERNMENT REFORM Many members of the Senate and House of Represent-atives do not know what has been going on. For example, the US Senate Committee on Government Reform had searched the archives in Washington and other places for the document titled The Special Virus Cancer Program: Progress Report No.8 mentioned above and couldn't find it. Somehow they heard I had it, called me and asked me to mail it to them. Imagine. A retired school teacher being called by the United States Senate and asked for one of their secret documents! The United States Senate through their government reform committee is trying to stop this type of government research.
BIOLOGICAL WARFARE RESEARCH AGREEMENT All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Great Britain entered into a secret agreement to create two types of biological weapons (one that would kill and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons. They primarily focused on brucellosis, and they began to weaponize the brucellosis bacteria.
CRYSTALLINE BRUCELLOSIS In a genuine U.S. Senate Study unclassified on February 24, 1977, the title page of this government record reports that George Merck, of the pharmaceutical company, Merck, Sharp and Dohme (which now makes cures for diseases they at one time created), in 1946, reported to the Secretary of War in the United States that his researchers had produced in isolation for the first time, a crystalline bacterial toxin extracted from brucellosis bacteria. The bacterial toxin could be removed in crystalline form and delivered by other vectors (in nature they are delivered within the bacteria). But the factor that is working in the brucellosis is the mycoplasma. Brucellosis is a disease agent that doesn't kill people; it disables them. But they found that if they had mycoplasma at a certain strength, actually ten to the tenth power, it would develop into AIDS, and the person would die from it within a reasonable period of time because it could bypass our natural human defences. If it was 108, the person would manifest with chronic fatigue syndrome or fibromyalgia. If it was 107, they would present as wasting; they wouldn't die, and they wouldn't be disabled, but they would not be that interested in life, they would waste away (ref. Dr. Donald MacArthur of the Pentagon appearing before a Congressional Committee, June 9, 1969, Department of Defence Appropriations, p.114, 129). Most of us have never heard of brucellosis because it largely disappeared when they began pasteurizing milk, which was the carrier. One salt shaker of this pure disease in a crystalline form could sicken the entire population of Canada. It is absolutely deadly, not in terms of killing the body, but in terms of disabling the body. The advantage of this crystalline disease agent is that it does not show up in blood and tissue tests because the bacteria has disappeared and only the pure disease agent remains. So the doctor thinks that it's all in your head.
CRYSTALLINE BRUCELLOSIS AND MULTIPLE SCLEROSIS About three years ago in Rochester, New York, a gentleman gave me a document and told me, "I was in the U.S. Army, and I was trained in bacteriological warfare. We were handling a bomb filled with brucellosis, only it wasn't brucellosis; it was a brucellosis toxin in crystalline form. We were spraying it on the Chinese and North Koreans." He showed me his certificate listing his training in chemical, biological, and radiological warfare. Then he showed me 16 pages of documents given to him by the U.S. military when he was discharged from the service. It linked brucellosis with multiple sclerosis and stated: "Veterans with multiple sclerosis, a kind of creeping paralysis developing to a degree of 10% or more disability within two years after separation from active service may be presumed to be service-connected for disability compensation. Compensation is payable to eligible veterans whose disabilities are due to service." In other words, "If you become ill with multiple sclerosis, it is because you were handling this brucellosis and we will give you a pension. Don't go raising any fuss about it." The government of the United States, in this official document revealed evidence of the cause of multiple sclerosis, but they didn't make it known to the public, or to your doctor. In a 1958 report, Drs. Kyger and Haden suggest "…the possibility that multiple sclerosis might be a central nervous system manifestation of chronic brucellosis". Testing approximately 113 MS patients, they found that almost 95% also tested positive for brucellosis. We have a document from a medical journal which concludes that one out of 500 people who had brucellosis would develop what they called neurobrucellosis, in other words, brucellosis in the brain which settles in the lateral ventricles where the disease multiple sclerosis is basically located.
CONTAMINATION OF CAMP DETRICK LAB WORKERS A report from the New England Journal of Medicine, 1948, Vol.236, p.741 called "Acute Brucellosis Among Laboratory Workers" shows us how actively dangerous this agent is. The laboratory workers were from Camp Detrick, Frederick, Maryland where they were developing biological weapons. Even though these laboratory workers had been vaccinated, wore rubberized suits and masks, and worked through holes in the compartment, many of them came down with this awful disease because it is so absolutely and terrifyingly infectious. The article was written by Lt. Calderone Howell, Marine Corps, Captain Edward Miller, Marine Corps, Lt. Emily Kelly, United States Naval Reserve and Captain Henry Bookman. They were all military personnel engaged in making the disease agent brucellosis into a more effective biological weapon.
III - Covert Testing of the Mycoplasma Testing Brucellis upon an Unsuspecting Public
Documented evidence proves that the biological weapons they were developing were tested on the public in various communities without their knowledge or consent. The government knew that crystalline brucellosis would cause disease in humans. Now they needed to determine how it spread, and the best way to disperse it. They tested dispersal methods for Brucella suis and Brucella melitensis at Dugway Proving Ground, Utah, June and September 1952. Probably, 100% of us now are infected with Brucella suis and Brucella melitensis. (ref. p.135, table 4 of Special Virus Cancer Program: Progress Report 8) . Another government document recommended the genesis of open air vulnerability tests, and covert research and development programs to be conducted by the army and supported by the Central Intelligence Agency. At that time, the government of Canada was asked by the government of the United States to cooperate in testing weaponized brucellosis, and Canada cooperated fully with the government of the United States. They wanted to determine (i) if mosquitoes will carry the disease and (ii) if the air will carry it. A government report stated that "…open air testing of infectious biological agents is considered essential to an ultimate understanding of biological warfare potentialities because of the many unknown factors affecting the degradation of micro-organisms in the atmosphere".
TESTING BRUCELLOSES VIA MOSQUITO VECTOR IN PUNTA GORDA
A report from The New England Journal of Medicine, August 22, 1957, p.362 reveals that one of the first outbreaks of chronic fatigue syndrome was in Punta Gorda, Florida, back in 1957. It was a strange coincidence that a week before these people came down with chronic fatigue syndrome, there was a huge influx of mosquitoes. The National Institutes of Health claimed that the mosquitoes came from a forest fire 30 miles away. When the forest fire broke out, the mosquitoes all said, "Well, let's go over to Punta Gorda - there will be a bunch of people over there, we can have a picnic, and then we will go home". The truth is that those mosquitoes were infected in Canada by Dr. J.B. Reed at Queen's University. They were bred in Belleville, Ontario, and taken down and released in Punta Gorda. Within a week, the first five cases ever of chronic fatigue syndrome were reported to the local clinic in Punta Gorda, and it continued until finally 450 people were ill with the disease.
TESTING BRUCELLOSIS VIA MOSQUITO VECTOR IN ONTARIO The government of Canada established the Dominion parasite Laboratory in Belleville, Ontario, and raised 100 million mosquitoes a month which were shipped to Queen's University and certain other facilities to be infected with this disease agent. The mosquitoes were then let loose in certain communities in the middle of the night so they could determine how many people would become ill with chronic fatigue syndrome, or fibromyalgia, which was the first disease to show. One of the communities they tested it on was the St. Lawrence Seaway valley all the way from Kingston to Cornwall in 1984. They let out absolutely hundreds of millions of infected mosquitoes. Over 700 people in the next four or five weeks developed myalgic encephalomyelitis, or chronic fatigue syndrome